C-(1-环戊基-哌啶-4-基)-甲胺 | 132864-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: C-(1-环戊基-哌啶-4-基)-甲胺
• 英文名称: C-(1-Cyclopentyl-piperidin-4-yl)-methylamine
• 英文别名: 1-(1-Cyclopentylpiperidin-4-YL)methanamine；(1-cyclopentylpiperidin-4-yl)methanamine
• CAS: 132864-60-9
• 化学式: C₁₁H₂₂N₂
• 分子量: 182.309
• InChiKey: DBQGQSUQRLEZFR-UHFFFAOYSA-N

物化性质

• 沸点：
  250.2±8.0 °C(Predicted)
• 密度：
  0.987±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  C-(1-环戊基-哌啶-4-基)-甲胺 、 3-[2-[2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid 在 N-乙基吗啉 、 O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(1-Cyclopentyl-Piperidin-4-Ylmethyl)-3-[2-(2,4-Dichloro-Phenyl)-Ethoxy]-4-Methoxy-Benzamide
  参考文献：
  名称：

  Structural Requirements for Factor Xa Inhibition by 3-Oxybenzamides with Neutral P1 Substituents:  Combining X-ray Crystallography, 3D-QSAR, and Tailored Scoring Functions

  摘要：

  The design, synthesis, and structure-activity relationship of 3-oxybenzamides as potent inhibitors of the coagulation protease factor Xa are described on the basis of X-ray structures, privileged structure motifs, and SAR information. A total of six X-ray structures of fXa/inhibitor complexes led us to identify the major protein-ligand interactions. The binding mode is characterized by a lipophilic dichlorophenyl substituent interacting with Tyr228 in the protease S1 pocket, while polar parts are accommodated in S4. This alignment in combination with docking allowed derivation of 3D-QSAR models and tailored scoring functions to rationalize biological affinity and provide guidelines for optimization. The resulting models showed good correlation coefficients and predictions of external test sets. Furthermore, they correspond to binding site topologies in terms of steric, electrostatic, and hydrophobic complementarity. Two approaches to derive tailored scoring functions combining binding site and ligand information led to predictive models with acceptable predictions of the external set. Good correlations to experimental affinities were obtained for both AFMoC (adaptation of fields for molecular comparison) and the novel TScore function. The SAR information from 3D-QSAR and tailored scoring functions agrees with all experimental data and provides guidelines and reasonable activity estimations for novel fXa inhibitors.

  DOI：

  10.1021/jm049187l

文献信息

• Serine protease inhibitors
  申请人：——

  公开号：US20040259868A1

  公开（公告）日：2004-12-23

  Compounds of formula (I) 1 in which R 2 , X, Y, Cy, L and Lp(D) n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

  式(I)的化合物，其中R2、X、Y、Cy、L和Lp(D)n的含义如规范中所述，是丝氨酸蛋白酶Xa的抑制剂，可用于治疗心血管疾病。
• Serine pretease inhibitors
  申请人：——

  公开号：US20030109706A1

  公开（公告）日：2003-06-12

  Compounds of formula (I) in which R 2 , X, Y, Cy, L and Lp(D) n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders. 1

  式(I)的化合物中，R2、X、Y、Cy、L和Lp(D)nhave的含义如规范中所述，是丝氨酸蛋白酶抑制剂，可用于治疗心血管疾病。
• Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs)
  申请人：Dong-A Socio Holdings Co., Ltd.

  公开号：US20160122343A1

  公开（公告）日：2016-05-05

  The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.

  本发明提供了一种式（I）的化合物，该化合物能够调节组蛋白赖氨酸去甲基化酶（KDM）的活性，以及其制备的药物组合物、制备所述化合物的方法，以及将这种化合物用作药物的用途。式（I）的化合物作为KDM抑制剂具有显著的效力，因此具有卓越的潜力用于药物干预癌症和与KDM失调相关的任何其他疾病。
• Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors
  作者：Andreas Blum、Dieter Dorsch、Nina Linde、Susanne Brandstetter、Hans-Peter Buchstaller、Michael Busch、Nina Glaser、Ulrich Grädler、Aaron Ruff、Carl Petersson、Hanno Schieferstein、Eva Sherbetjian、Christina Esdar

  DOI：10.1021/acs.jmedchem.2c00851

  日期：2023.2.23
• SERINE PROTEASE INHIBITORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1289954A1

  公开（公告）日：2003-03-12